| Learn and connect with others who are affected by Type 1 Gaucher disease | | | | | | | | | | | | | Announcing  | | | | Wednesday, September 13, 2017
Registration Time: 11:30 AM
Program Start Time: 12:00 PM Hilton Garden Inn New York/Central Park South-Midtown West 237 W 54th Street
New York, NY 10019 | | | | Featured Speaker: Ozlem Goker-Alpan, MD | | | | Journey with Gaucher is an event exclusive to people whose lives have been touched by Type 1 Gaucher disease. Whether you're a patient or caregiver, join us for an opportunity to: | • | Learn more about Type 1 Gaucher disease from a guest physician | | • | Listen to an informed conversation about health and wellness, including: | | | • | Exercise | | • | Maintaining Relationships | | | • | Nutrition | | • | Dental Health | | | • | Ownership of Your Type 1 Gaucher Disease | | • | Family Planning and more | | | • | Connect with others to share your personal experience | | | | | This event will be led by a trained moderator.
Light refreshments will be served. | | | | Register Today | | | | | | | | For more information about
Type 1 Gaucher disease and ELELYSO,
visit www.ELELYSO.com. | | | | INDICATION
ELELYSO® (taliglucerase alfa) for injection is indicated for the treatment of patients with a confirmed diagnosis of Type 1 Gaucher disease. IMPORTANT SAFETY INFORMATION
Serious hypersensitivity reactions including anaphylaxis have occurred in some patients treated with ELELYSO® (taliglucerase alfa) for injection. When treated with ELELYSO your doctor should monitor you before and after infusion for reactions. Medical support should be readily available when ELELYSO is given. Discontinue ELELYSO immediately if you show signs or symptoms of anaphylaxis during infusion and get immediate medical care. Signs and symptoms of anaphylaxis include hives, low blood pressure, flushing, wheezing, chest tightness, nausea, vomiting, and dizziness. Signs and symptoms of hypersensitivity include itching, swelling under the skin, flushing, redness, rash, nausea, vomiting, cough, chest tightness, and throat irritation. These reactions occurred up to 3 hours after the start of infusion. Management of hypersensitivity reactions is based on the severity of the reaction. Your doctor may manage the reactions by slowing or temporarily stopping the infusion, and/or treating with medications such as an antihistamine, a fever reducer, and/or corticosteroids for mild reactions. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions from reoccurring. If severe hypersensitivity reactions occur, immediately stop the infusion of ELELYSO and get immediate medical care. You should be carefully re-evaluated for treatment with ELELYSO if serious or hypersensitivity reactions including anaphylaxis occur. The most common adverse reactions for ELELYSO are itching, flushing, headache, joint pain, pain in extremity, abdominal pain, vomiting, diarrhea, fatigue, back pain, dizziness, nausea, and rash. Vomiting occurred more often in children than adults and this may be due to a hypersensitivity reaction. The occurrence of other adverse reactions was similar between children and adults. The recommended dosage of ELELYSO for adults and children who are 4 years of age and older and not taking another enzyme replacement therapy (ERT) is 60 Units per kg of body weight given every other week as a 60- to 120-minute intravenous infusion. As with all therapeutic proteins, including ERTs, there is a possibility of developing antibodies to ELELYSO. The relationship between developing antibodies and hypersensitivity reactions is not clear. Your doctor should monitor you for antibodies to ELELYSO if you have developed antibodies or if you have experienced hypersensitivity reactions to ELELYSO or other ERTs. If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks. ELELYSO is supplied as 200 Units per vial and is available by prescription only. Please click here for Full Prescribing Information. | | | | | | | | |  | | | To unsubscribe from emails regarding programs in your area, please reply "unsubscribe" to unsubscribe to this email. If you no longer wish to receive professional marketing email communications from Pfizer, unsubscribe here. If you wish to contact Pfizer, click here. View the Pfizer Privacy Policy here. Pfizer ELELYSO
P.O. Box 29387
Mission, KS 66201-5309 This advertisement is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. Decisions regarding patient care must be made with a healthcare provider. Intended for U.S. audiences only. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. | | | |
No comments:
Post a Comment